Moderna, Inc MRNA shares are trading higher Wednesday. The company announced positive data from its combination vaccine against influenza and Covid-19.
What To Know: Moderna highlighted positive interim results from its Phase 1/2 trial of mRNA-1083, the company's investigational vaccine for the flu and Covid.
The combination vaccine was compared to the Spikevax booster in the trials. Moderna said it achieved hemagglutination inhibition antibody titers similar to or greater than both licensed quadrivalent flu vaccines. It also achieved SARS-CoV-2 neutralizing antibody titers similar to the Spikevax bivalent booster.
mRNA-1083 has been selected to advance to Phase 3 trials. Moderna is targeting regulatory approval for the vaccine in 2025.
"Combination vaccines offer an important opportunity to improve consumer and provider experience, increase compliance with public health recommendations, and deliver value for healthcare systems," said Stéphane Bancel, CEO of Moderna.
"We are excited to move combination respiratory vaccines into Phase 3 development and look forward to partnering with public health officials to address the significant seasonal threat posed to people by these viruses."
Related Link: Bill Gates Applauds Nobel Laureates Katalin Kariko And Drew Weissman Behind Revolutionary mRNA COVID-19 Vaccines
On Tuesday, shares of competitor Novavax Inc NVAX surged after the U.S. Food and Drug Administration granted Emergency Use Authorization for the company's updated Covid-19 vaccine. The FDA approved Moderna's updated vaccine in early September.
MRNA Price Action: Moderna shares were up 0.85% at $103.96 at the time of publication, according to Benzinga Pro.
Photo: Mufid Majnun from Pixabay.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
